Subscribe to the newsletterForward | Contact |   September 2010
Big Loan: Lyonbiopole, candidate for the creation of an Institute for Technological Research in «infectious diseases» in Lyon-Gerland

In response to the Call for Expression of Interest (MAI) launched by the General Commission for future investments, Lyonbiopole has submitted its proposal last Friday, September 10th 2010, with the aim to establish in Lyon an Institute for Technological Research (IRT) dedicated to Biomedical Innovation in Infectious Diseases.

Learn more

Lyonbiopole starts the construction of acCInov, a 6.000 sq.m/ 10.76 sq. ft innovation plateform based in Lyon-Gerland

Second step of the Lyonbiopole’s infrastructure policy dedicated to cover all the links in the chain of innovation in infectious diseases, acCInov is a continuation of the Infectious Diseases Center which opened last April 2009. This new area will be dedicated to the hosting of new or emerging start-ups and SMBs, which will provide services in the areas of bioanalysis and bioproduction for the development of new products for preventive, therapeutic or diagnostic applications.

Learn more

Reminder : Don’t forget to register to the 4th Edition of the Lyonbiopole’s Partnering Days

This year, the Lyonbiopole’s Partnering Days will be held on October 7th, 2010 at the World Trade Center in Grenoble. Registration Deadline: October 1st, 2010.
Contact: Claudia Chagneau, Project Manager

Learn more

SMB and private funding: "How to strengthen your equity capital ?”: registration is now open!

This second edition, organized in partnership with CREALYS and OSEO, will be held on Friday, December 3rd, 2010 at the headquarters of Sanofi Pasteur in Lyon-Gerland. This event is dedicated to innovative companies and biotech company’s project leaders. 
Contact: Isabelle Scarabin, Director of Economic and International Affairs

Learn more

Indicia Biotechnology

For more than ten years, Indicia Biotechnology has been committed to support the bioindustry in their R&D projects by providing custom immunoassay development services for diagnostic or research use. Today, the company addresses the mutation of the pharmaceutical market and is positioning itself as a CRO (Contract Research Organization) specialized for the measurement of protein biomarkers thanks to a new service of sample bioanalyse.

Learn more

Business convention BIOPHARM AMERICA in Boston

Lyonbiopole participate this week with 5 Rhône-Alpes companies members of Lyonbiopole to the BIOPHARM AMERICA convention, Boston organized by EBD , preceeded by the French Biotech Tour East Coast organized by Ubifrance.

Learn more

Register you to the 2nd edition of the 2nd French-Quebec competitiveness clusters

In partnership with Lyonbiopole and the other French health clusters, the Alsace BioValley cluster will welcome in Alsace, on November 24th and 25th, 2010: the "Biotechnologies Health" regional days in the framework of the 2nd French-Quebec competitiveness clusters and clusters of excellence symposium, organized by the French Ministry of Economy, Industry and Employment. Lyonbiopole is a partner of these meetings. For register you until October 15th, 2010 on the website: .
Contact : kevin Romani, International project manager :

Learn more

Lyonbiopole organize a franco-swiss meeting on the occasion of the BioAlps Networking Day

The BioAlps Networking Day is an annual event free of charge organized bty BioAlps (Lake Geneva Biocluster Switzerland). It will be held on September 29th, 2010 at the Merck-Serono Headquarter in Geneva and will address the following topic: “Personalised Medicine – Medicines Made To Measure”. For this occasion, Lyonbiopole in collaboration with BioAlps, will organize during the afternoon, a franco-swiss networking event dedicated to Lyonbiopole members. Contact :

Learn more

Launch of the first event Biofit 2010 organized by Biofit Eurasanté and IDIS in partnership with EBD Group

This new international pharma-tech transfer event 'Biofit' will be held on October 26th and 27th, 2010 in Lille. Biofit is positioned to become a leading event focused on biotechnology innovation.
Contact : Kevin Romani, International project manager :

Learn more

Franco-Chinese innovation meetings in China

These meetings will be held from October 17th to 21st, 2010, in Chengdu and other Chinese cities. This event, proposed by the DGCIS in partnership with UbiFrance and its French Economic Missions in China, aims to support the French competitiveness clusters and their companies willing to develop industrial and technological partnerships in China, in particular through the organization of BtoB meetings in Chengdu, Beijing, Shangaï or Shenzhen.

Learn more

International Symposium: "The viral pandemics are now eradicable: is it what we really want to?"

As part of the 23rd  edition of  the “Entretiens du Centre Jacques Cartier”, this symposium is organized by the Centre Jacques Cartier in partnership with the Regional Cluster "Infectious Diseases" on November 22nd  and 23rd , 2010 in the Aula Magna of the Lyon 1 University  ( Lyon 7). Lyonbiopole is a member of the Steering Committee and will participate to the event.

Learn more

The next appointment in Life Sciences' field:  

BioPharm America,

September from 15th to 17th, 2010, Boston


ECCP 2010 - European Cancer Cluster Partnering,

September from 15th to 17th, 2010, Oslo



September from 29th to October 1st, 2010, Tokyo


Grenoble Innovation Fair,

October 5th and 6th, 2010, Grenoble


Bio Contact, 

October 6th and 7th, 2010, Québec


4th edition of Lyonbiopole's Partnering Days,

October 7th, 2010, Grenoble


BioAlps Networking Day,

September 29th, 2010, Geneva


Herd Immunity/Protection: an Important Indirect Benefit of Vaccination,

October from 25th to 27th, 2010, “Les Pensières”  Fondation Mérieux Conference Center, Veyrier du Lac


Biofit 2010 - Fostering Innovation & Transfer,

October 26th to 27th, 2010, Lille


6th édition of Competitiveness cluster Forum,

November 18th and 19th, 2010,Sophia Antipolis


Les Entretiens du Centre Jacques Cartier - 23rd edition,

November 22th to 23rd, Lyon


France-Quebec Symposium,

November 24th to 26th, 2010, France


SMB and private investors : "Hw to strengthen your equity capital?"

December 3rd, 2010, Sanofi Pasteur, Lyon



March from 27th to 29th, 2011, Lyon


Bio International Convention,

June from 27th to 30th, 2010, Washington

Focus on the project calls for the program “Investment for the Future” (Big loan)

The "Investment for the Future" has a total budget of € 35 billion that will be mobilized under the French Grand Loan. € 21.9 billion will be dedicated to higher education and research. 

Learn more

Call for proposals 2011 "Research for the benefit of SMBs" of the FP7 capabilities programme

The European Commission has published last July 20th , 51 “calls for proposals 2011”  within the framework of the FP7. These calls refer to the 4 programs of the FP7: Cooperation, Ideas, People and Capacities. A call capabilities, currently open, is dedicated to the "Research for SMEs". This call will be closed  on December 8th, 2010.
Contact : Safia Arours, chargée de projets :

Learn more

European Workshop on EDCTP - European and Developing Countries Clinical Trials Partnership

Lyonbiopole organises a European Workshop on the EDCTP calls on October 15th 2010 from 12.00 to 17.00. Contact : Safia Arous, projects manager

Learn more

The Lyonbiopole’s R&D projects : PRAVIC

Accredited by the Lyonbiopole cluster, the PRAVIC program initiated in 2005 and developed by iDD biotech was financially supported by the French State. The PRAVIC program assembled competencies from OPi (initially), the Lyon Civil Hospital, the Leon Berard Center and PX’Therapeutics. The aim of PRAVIC project was the R&D of new therapeutic monoclonal antibodies (MAbs) for the treatment of haematological malignancies of viral or non virus origin.

Learn more

6 new R&D projects accredited by Lyonbiopole have obtained public funding in 2010 from the 9th and 10th Calls for Projects of the Single Inter-Ministry Fund (FUI)

The projects COVADIS, POLYBIO, RHENEPI (for the 9th call), EMER FAB, FEMTOKINE and OPTIMAB (for the 10th call), coordinated by SMBs or industrials, in collaboration with research centers, have been selected by the FUI. They represent a global investment of € 20 million and will receive € 10,1 million of public funding (FUI)

Learn more

The private investor Vizille Capital Innovation meets the members of Lyonbiopole

In the framework of the investor meetings, Lyonbiopole provides an opportunity for its members and project leaders followed by Crealys and Grain to meet individually private investor : Vizille Capital Innovation on September 28th, 2010
Contact : 

Learn more

1st meeting for the Bio Biz Dev Club of Lyonbiopole

On September 28th, 2010, Lyonbiopole launches the Bio Biz Dev Club. This new initiative aims to create moments for exchanges dedicated and reserved to business developers coming from Lyonbiopole’s member companies. 2 to 3 meetings will be organized each year around specific topics linked to Business Development.
Contact : kevin Romani, International Project Manager :

Learn more

Singulex launches presence in Europe

Singulex, Inc., the leaderinhigh-definition immunodiagnostic technology has set up its first European R&D center in France in association with the Lyon-based innovation cluster Lyonbiopole.  In addition to supporting cutting edge research in the treatment of inflammatory and cardiovascular disease, the new location will provide sales and technical support to European clients.  Beginning this month in partnership with Lyon-based Indicia Biotechnology, Singulex will introduce its distinctive portfolio of immunoassay technology to the European biotech and pharmaceutical market. 

Learn more

Glycode joins the Lyonbiopole Business Center

Glycode is a biotechnology company which aims to become a leader in the field of protein glycosylation. Founded in 2004, the company has developed a proprietary innovative and powerful technology, GlycodExpress™, which consists of a bank of yeast strains genetically optimized for the production of recombinant therapeutic glycoproteins (antibodies, EPOs, growth factors…). These strains have been genetically glycol engineered to synthesize fully humanized N-glycans. Glycode raised 3M€ from Sofimac Partners, Octalfa, Sham and Limousin Participations.

Learn more

Khorionyx obtains I.N.D. of the FDA

This approval will allow Khorionyx to realise a first clinical study of autologous human globin on 15 patients in the USA. Contact :

Learn more

Ecrins therapeutics become a company

Ecrins Therapeutics SAS has been registered on July 21st, 2010. The company was founded by Dr. Aurelie JUHEM, Dr.Andrei Popov (CEO) and Prof. Francois BERGER. The mission of Ecrins Theurapeutics is to develop innovative cancer drugs.
Contact :
© Lyonbiopole 2021  |  CREDITS  |  LEGAL NOTICE  |